Literature DB >> 24871326

Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.

Yongsheng Li1, Shengli Li1, Juan Chen1, Tingting Shao1, Chunjie Jiang1, Yuan Wang1, Hong Chen1, Juan Xu2, Xia Li2.   

Abstract

Breast cancer is a highly heterogeneous disease that is characterized by genetic and epigenetic aberrations; however, our knowledge of epigenetic alterations of breast cancer subtypes remains limited. Here, we portrayed and compared the alterations of six types of histone modifications and DNA methylation between two breast cancer subtypes, luminal and basal. Widespread subtype-specific epigenetic alterations were observed in both subtypes, which preferentially occurred within CpG islands (CGIs) and promoter regions. Specifically, aberrant DNA methylation was mostly located inside CGIs in luminal subtype, whereas in basal subtype it was principally located within CGI shores. Moreover, different types and combinatorial patterns of epigenetic alterations were found to occupy at promoter regions between these two subtypes. And these epigenetic alterations regulated corresponding gene expression in a synergetic way in both subtypes. Functional enrichment analysis highlighted that epigenetically dysregulated genes were significantly involved in the hallmarks of cancers, most of which were subtype specific. Even genes involved in the same hallmarks associated biological processes were affected by various types of epi-modifications in different subtypes. Finally, we revealed distinct patterns of oncogenic pathways activation in different subtypes and provided novel insights into subtype specific therapeutic opportunities. In addition, genes in the key signaling pathways were able to discriminate between disease phenotypes, and subtype-specific progression associated genes were identified. This study presents the aberrant epigenetic patterns of breast cancer subtypes at a genome-wide level, which will be a highly valuable resource for investigations at understanding epigenetic regulation of breast cancer subtypes.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24871326     DOI: 10.1093/hmg/ddu256

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Richard D Emes; John R Glossop; Christopher Luscombe; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Charles A Mein; Lyndon Gommersall; Anthony A Fryer; William E Farrell
Journal:  Epigenetics       Date:  2016-03-01       Impact factor: 4.528

2.  Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.

Authors:  Ferdinando Chiaradonna; Iros Barozzi; Claudia Miccolo; Gabriele Bucci; Roberta Palorini; Lorenzo Fornasari; Oronza A Botrugno; Giancarlo Pruneri; Michele Masullo; Alfonso Passafaro; Viviana E Galimberti; Valeria R Fantin; Victoria M Richon; Salvatore Pece; Giuseppe Viale; Pier Paolo Di Fiore; Giulio Draetta; Pier Giuseppe Pelicci; Saverio Minucci; Susanna Chiocca
Journal:  Antioxid Redox Signal       Date:  2015-05-27       Impact factor: 8.401

3.  Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Ya-Zhen Qin; Yan-Huan Zhang; Xiao-Ying Qin; Hong-Hu Zhu
Journal:  Oncol Lett       Date:  2017-02-28       Impact factor: 2.967

4.  IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.

Authors:  Li-Teng Ong; Wee Chyan Lee; Shijun Ma; Gokce Oguz; Zhitong Niu; Yi Bao; Mubaraka Yusuf; Puay Leng Lee; Jian Yuan Goh; Panpan Wang; Kylie Su Mei Yong; Qingfeng Chen; Wenyu Wang; Adaikalavan Ramasamy; Dave S B Hoon; Henrik J Ditzel; Ern Yu Tan; Soo Chin Lee; Qiang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

5.  FACER: comprehensive molecular and functional characterization of epigenetic chromatin regulators.

Authors:  Jianping Lu; Juan Xu; Junyi Li; Tao Pan; Jing Bai; Liqiang Wang; Xiyun Jin; Xiaoyu Lin; Yunpeng Zhang; Yongsheng Li; Nidhi Sahni; Xia Li
Journal:  Nucleic Acids Res       Date:  2018-11-02       Impact factor: 16.971

6.  The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer.

Authors:  Seher Karsli-Ceppioglu; Aslihan Dagdemir; Gaëlle Judes; André Lebert; Frédérique Penault-Llorca; Yves-Jean Bignon; Dominique Bernard-Gallon
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

7.  Competing endogenous RNA network analysis identifies critical genes among the different breast cancer subtypes.

Authors:  Juan Chen; Juan Xu; Yongsheng Li; Jinwen Zhang; Hong Chen; Jianping Lu; Zishan Wang; Xueying Zhao; Kang Xu; Yixue Li; Xia Li; Yan Zhang
Journal:  Oncotarget       Date:  2017-02-07

8.  SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer.

Authors:  Khaldoun Rifaï; Gaëlle Judes; Mouhamed Idrissou; Marine Daures; Yves-Jean Bignon; Frédérique Penault-Llorca; Dominique Bernard-Gallon
Journal:  Oncotarget       Date:  2018-07-17

9.  Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer.

Authors:  Mark O Kitchen; Richard T Bryan; Kim E Haworth; Richard D Emes; Christopher Luscombe; Lyndon Gommersall; K K Cheng; Maurice P Zeegers; Nicholas D James; Adam J Devall; Anthony A Fryer; William E Farrell
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

10.  Luminal B breast cancer subtype displays a dicotomic epigenetic pattern.

Authors:  Naiara G Bediaga; Elena Beristain; Borja Calvo; María A Viguri; Borja Gutierrez-Corres; Ricardo Rezola; Irune Ruiz-Diaz; Isabel Guerra; Marian M de Pancorbo
Journal:  Springerplus       Date:  2016-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.